OncoMatch/Clinical Trials/NCT07319871
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
Is NCT07319871 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including Pasritamig and JNJ-86974680 for prostatic neoplasms.
Treatment: Pasritamig · JNJ-86974680 — The purpose of this study is to identify the recommended phase 2 combination dose (RP2CD) of Pasritamig in combination with JNJ-86974680 in Part 1 (Dose finding) of the study and to determine how safe and tolerable the RP2CD is for treatment of participants with advanced prostate cancer in Part 2 (Dose expansion) of study.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Biomarker criteria
Required: KLK3 PSA ≥ 2 ng/mL (≥ 2 ng/mL)
Prostate-specific antigen (PSA) greater than or equal to (≥) 2 nanograms per milliliters (ng/mL) at screening
Disease stage
Required: Stage METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Metastatic disease required
Metastatic castration-resistant prostate cancer (mCRPC) that is metastatic either to bone, any lymph node, or both without clear evidence of metastasis to visceral organs. Local-regional invasion (rectum, bladder) and bone disease with soft tissue component can be included
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: androgen deprivation therapy (orchiectomy, gonadotropin-releasing hormone (GnRH) analog (agonist or antagonist)) — ongoing
Prior orchiectomy or medical castration (for example, must be receiving ongoing androgen deprivation therapy with a gonadotropin-releasing hormone [GnRH] analog [agonist or antagonist] prior to the first dose of study drug and must continue this therapy throughout the treatment phase)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Florida Cancer Specialists · Sarasota, Florida
- Columbia University Medical Center · New York, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07319871 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received androgen deprivation therapy.
Does this trial require KLK3?
Yes, KLK3 PSA ≥ 2 ng/mL is a required biomarker for enrollment.
What disease stage is eligible?
Stage METASTATIC CASTRATION-RESISTANT PROSTATE CANCER is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages